Current use of combined hormonal contraception is associated with glucose metabolism disorders in perimenopausal women
Mosorin, Maria-Elina; Haverinen, Annina; Ollila, Meri-Maija; Nordström, Tanja; Jokelainen, Jari; Keinänen-Kiukaanniemi, Sirkka; Puukka, Katri; Ruokonen, Aimo; Auvinen, Juha; Piltonen, Terhi; Morin-Papunen, Laure; Tapanainen, Juha S (2020-12-31)
Mosorin, M., Haverinen, A., Ollila, M., Nordström, T., Jokelainen, J., Keinänen-Kiukaanniemi, S., Puukka, K., Ruokonen, A., Auvinen, J., Piltonen, T., Morin-Papunen, L., & Tapanainen, J. S. (2020). Current use of combined hormonal contraception is associated with glucose metabolism disorders in perimenopausal women, European Journal of Endocrinology, 183(6), 619-626. Retrieved Mar 16, 2022, from https://eje.bioscientifica.com/view/journals/eje/183/6/EJE-20-0406.xml
© 2020 European Society of Endocrinology. The final authenticated version is available online at https://doi.org/10.1530/EJE-20-0406.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe2022031623824
Tiivistelmä
Abstract
Objective: The use of combined hormonal contraceptives (CHCs) worsens glucose tolerance, but the risk for glucose metabolism disorders remains controversial.
Design: The study is a prospective longitudinal population-based cohort study.
Methods: The study was based on a cohort population that comprised 1879 women born in 1966. At age 46, the women answered a questionnaire on contraceptive use and underwent an oral glucose tolerance test. Glucose metabolism indices were evaluated in current CHC (n = 153), progestin-only contraceptive (POC, n = 842), and non-hormonal contraceptive users (n = 884).
Results: In the entire study population, current CHC use was significantly associated with prediabetes (OR: 2.0, 95% CI: 1.3–3.2) and type 2 diabetes (OR: 3.3, 95% CI: 1.1–9.7) compared to non-hormonal contraceptive use. After 5 years of use, the prediabetes risk increased 2.2-fold (95% CI: 1.3–3.7) and type 2 diabetes risk increased 4.5-fold (95% CI: 1.5–13.5). Compared with the current POC use, current CHC use was significantly associated with prediabetes (OR: 1.9, 95% CI: 1.2–3.0). Current POC use was not associated with any glucose metabolism disorders. The results prevailed after adjusting for BMI and socioeconomic status.
Conclusions: CHC use in perimenopausal women was associated with a significantly increased risk of glucose metabolism disorders. This association should be considered in women with increased metabolic risk.
Kokoelmat
- Avoin saatavuus [38618]